Predictors of failure of non-invasive ventilation in severe COVID-19 patients
Keywords:NIV, COVID-19, ROX index
Background: Respiratory oxygenation index (ROX index) is a simple parameter that uses bedside parameters like respiratory rate and peripheral oxygen saturation. It has been extensively evaluated to predict success of HFNC in patients with pneumonia and found beneficial in predicting HFNC failure. However, there are very few literatures are available to establish the efficacy of ROX index in predicting NIV success. The aim of this study was to determine whether the ROX Index could predict NIV therapy success in patients with AHRF due to SARS-CoV-2 pneumonia.
Methods: After obtaining approval and clearance from the institutional ethics committee of BMCRI, patients who were admitted in Victoria Hospital intensive care unit with acute respiratory failure due to COVID-19 who were initiated on NIV or CPAP based on clinician decision during the study period of April 2020 – July 2021 were included.
Results: The optimal cut-off value of ROX index for predicting ventilatory requirement according to the maximum Youden index was ≤3.93. This cut-off value showed a sensitivity of 89.83% and a specificity of 92.86%, and the AUC was 0.965 (95% CI 0.909 to 0.992, P<0.0001).
Conclusions: When compared between ROX index, SPO2 at Room air and CT Score, it was observed that ROX index had the highest, AUROC, sensitivity, and specificity. This indicates that ROX index can be used as a predictive variable for NIV failure or success.
World Health Organization. Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19: a module from the suite of health service capacity assessments in the context of the COVID-19 pandemic: interim guidance, 20 October 2020. World Health Organization. 2020.
Lazzeri M, Lanza A, Bellini R, Bellofiore A, Cecchetto S, Colombo A et al. Respiratory physiotherapy in patients with COVID-19 infection in acute setting: a Position Paper of the Italian Association of Respiratory Physiotherapists (ARIR). Monaldi Archives for Chest Disease. 2020;90(1).
Righetti RF, Onoue MA, Politi FV, Teixeira DT, Souza PN, Kondo CS et al. Physiotherapy care of patients with coronavirus disease 2019 (COVID-19)-a Brazilian experience. Clinics. 2020;75.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497-506.
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX et al. Clinical characteristics of coronavirus disease 2019 in China. New England J Med. 2020;382(18):1708-20.
Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. JAMA. 2020;323(16):1545-6.
Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Med. 2020;8(5):475-81.
Spoletini G, Hill NS. High-flow nasal oxygen versus noninvasive ventilation for hypoxemic respiratory failure: Do we know enough?. Ann Thoracic Med. 2016;11(3):163.
Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020;46(5):854-87.
Roca O, Caralt B, Messika J, Samper M, Sztrymf B, Hernández G et al. An index combining respiratory rate and oxygenation to predict outcome of nasal high-flow therapy. Am J Res Critical Care Med. 2019;199(11):1368-76.
Rapp JL, Lieberman-Cribbin W, Tuminello S, Taioli E. Male sex, severe obesity, older age, and chronic kidney disease are associated with COVID-19 severity and mortality in New York City. Chest. 2021;159(1):112-5.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9.
Alizadehsani R, Sani AZ, Behjati M, Roshanzamir Z, Hussain S, Abedini N et al. Risk factors prediction, clinical outcomes, and mortality in COVID‐19 patients. J Med Virol. 2021;93(4):2307-20.
Festic E, Bansal V, Kor DJ, Gajic O. US Critical Illness and Injury Trials Group: Lung Injury Prevention Study Investigators (USCIITG–LIPS). SpO2/FiO2 ratio on hospital admission is an indicator of early acute respiratory distress syndrome development among patients at risk. J Intensive Care Med. 2015;30(4):209-16.
Gandhi RT, Lynch JB, Del Rio C. Mild or moderate Covid-19. New England Journal of Medicine. 2020;383(18):1757-66.
Zucman N, Mullaert J, Roux D, Roca O, Ricard JD. Prediction of outcome of nasal high flow use during COVID-19-related acute hypoxemic respiratory failure. Intensive Care Med. 2020;46(10):1924-6.
Hasanin A, de Vasconcellos K, Abdulatif M. COVID-19 in Africa: current difficulties and future challenges considering the ACCCOS study. Anaesthesia, Critical Care Pain Med. 2021;40(4):24-8.
Mukhtar A, Lotfy A, Hasanin A, El-Hefnawy I, El Adawy A. Outcome of non-invasive ventilation in COVID-19 critically ill patients: a retrospective observational study. Anaesthesia, Critical Care Pain Med. 2020;39(5):579.
Mahdjoub E, Mohammad W, Lefevre T, Debray MP, Khalil A. Admission chest CT score predicts 5-day outcome in patients with COVID-19. Intensive Care Med. 2020;46(8):1648-50.